Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 03 2022 - 04:05PM
Business Wire
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that Javier Szwarcberg, M.D., MPH,
Chief Executive Officer, and Samir Gharib, President and Chief
Financial Officer, will participate in a virtual fireside chat at
the SVB Leerink 11th Annual Global Healthcare Conference on
February 17, 2022 at 5:00pm EST.
Interested parties can access the live webcast for the
conference from the Events section of the company’s investor
relations website at https://investors.sprucebiosciences.com. An
archived replay of the webcast will be available after the
conclusion of the live presentation for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal therapy for
patients suffering from classic congenital adrenal hyperplasia
(CAH). Classic CAH is a serious and life-threatening disease with
no known novel therapies approved in approximately 50 years. Spruce
is also developing tildacerfont for women suffering from a rare
form of polycystic ovary syndrome (PCOS) with primary adrenal
androgen excess. To learn more, visit www.sprucebiosciences.com and
follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220203005034/en/
Media Contact Will Zasadny Canale Communications (619)
961-8848 will.zasadny@canalecomm.com media@sprucebiosciences.com Investors Xuan
Yang Solebury Trout (415) 971-9412 xyang@soleburytrout.com
investors@sprucebiosciences.com
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
From Mar 2023 to Mar 2024